NasdaqGS:GHHealthcare
Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test
Why Guardant Health Stock Is Back on Investors’ Radar
Guardant Health (GH) moved into focus after several Q2 2026 developments, including FDA approval of an updated Guardant360 liquid biopsy test and new American Cancer Society support for its Shield colorectal cancer screening.
These clinical and guideline milestones arrived alongside stronger than expected Q1 results related to test volume and coverage trends. This provided investors with fresh information on how the company’s product...